Artemis Investment Management LLP Sells 80,004 Shares of Repligen Co. (NASDAQ:RGEN)

Artemis Investment Management LLP reduced its stake in Repligen Co. (NASDAQ:RGEN) by 47.7% during the 2nd quarter, Holdings Channel reports. The fund owned 87,809 shares of the biotechnology company’s stock after selling 80,004 shares during the period. Artemis Investment Management LLP’s holdings in Repligen were worth $11,069,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. YHB Investment Advisors Inc. bought a new position in Repligen in the 1st quarter valued at about $26,000. Lazard Asset Management LLC raised its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares during the period. Principal Securities Inc. bought a new position in Repligen in the 4th quarter valued at about $48,000. Finally, CWM LLC increased its holdings in shares of Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and lowered their target price for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating on the stock. UBS Group reduced their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $190.00 price target on shares of Repligen in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $189.57.

Repligen Price Performance

Shares of NASDAQ RGEN traded down $1.73 during midday trading on Monday, reaching $163.43. 196,031 shares of the company were exchanged, compared to its average volume of 640,708. The stock’s 50-day moving average price is $136.04 and its 200-day moving average price is $165.48. The stock has a market cap of $9.13 billion, a P/E ratio of 660.64, a PEG ratio of 5.85 and a beta of 0.95. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis. On average, sell-side analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus acquired 1,615 shares of Repligen stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, Director Martin D. Madaus acquired 1,615 shares of Repligen stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anthony Hunt bought 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the acquisition, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.